Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company headquartered in Cleveland, United States, continues to make significant strides in the biotechnology sector. Specializing in the development of novel gene therapies, Abeona is dedicated to addressing life-threatening rare diseases. The company’s commitment to innovation is reflected in its strategic focus and ongoing research initiatives.

As of October 9, 2025, Abeona Therapeutics Inc. is listed on the Nasdaq stock exchange, with a closing price of $5.36. The company’s market capitalization stands at approximately $290.24 million, indicating its substantial presence in the healthcare sector. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of $7.54 on August 14, 2025, and a 52-week low of $3.93 on April 8, 2025.

Abeona’s financial metrics reveal a price-to-earnings (P/E) ratio of 9.91, suggesting investor confidence in its growth potential and the effectiveness of its research endeavors. The company’s focus on gene therapy positions it at the forefront of biotechnological advancements, aiming to provide transformative treatments for patients with rare genetic disorders.

Since its Initial Public Offering (IPO) on September 19, 1980, Abeona Therapeutics Inc. has evolved into a leader in its field, driven by a mission to develop cutting-edge therapies. The company’s efforts are centered around leveraging gene therapy to offer hope and improved quality of life for individuals affected by rare diseases.

For more information about Abeona Therapeutics Inc. and its ongoing projects, stakeholders and interested parties are encouraged to visit the company’s official website at www.abeonatherapeutics.com . As Abeona continues to advance its research and development initiatives, it remains committed to its mission of transforming the landscape of rare disease treatment through innovative gene therapy solutions.